Comments

An NHS-supported weight-loss scheme has revealed it will keep the price of its Mounjaro treatment steady for current clients this September, despite the medication's maker imposing cost increases of up to 170 per cent. Second Nature, which provides two drug-assisted programmes, stated the decision aims to shield patients from "sudden treatment interruption" whilst the marketplace adjusts. ‌

The revelation follows Eli Lilly's confirmation that from September 1, costs for Mounjaro - a weekly injectable slimming medication increasingly given for obesity and type 2 diabetes - would climb sharply across all dosages. Chris Edson, CEO and co-founder of Second Nature, stated numerous patients on private schemes will now confront tough choices, reports Surrey Live . ‌

"There are a

See Full Page